CN114729020A - 长效gdf15融合蛋白及包含其的药物组合物 - Google Patents

长效gdf15融合蛋白及包含其的药物组合物 Download PDF

Info

Publication number
CN114729020A
CN114729020A CN202080081137.8A CN202080081137A CN114729020A CN 114729020 A CN114729020 A CN 114729020A CN 202080081137 A CN202080081137 A CN 202080081137A CN 114729020 A CN114729020 A CN 114729020A
Authority
CN
China
Prior art keywords
val
pro
ser
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081137.8A
Other languages
English (en)
Chinese (zh)
Inventor
林世荣
朴永奉
金秀劲
沈博拉
朱美敬
梁智银
崔铉浩
郑元晖
金元泰
李允雨
金埈焕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of CN114729020A publication Critical patent/CN114729020A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080081137.8A 2019-11-26 2020-11-25 长效gdf15融合蛋白及包含其的药物组合物 Pending CN114729020A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190153680 2019-11-26
KR10-2019-0153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
CN114729020A true CN114729020A (zh) 2022-07-08

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081137.8A Pending CN114729020A (zh) 2019-11-26 2020-11-25 长效gdf15融合蛋白及包含其的药物组合物

Country Status (11)

Country Link
US (1) US20230002460A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065597A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023503472A (cg-RX-API-DMAC7.html)
KR (1) KR20210065057A (cg-RX-API-DMAC7.html)
CN (1) CN114729020A (cg-RX-API-DMAC7.html)
AU (1) AU2020394255B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161302A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006173A (cg-RX-API-DMAC7.html)
WO (1) WO2021107603A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204624B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069921A1 (en) * 2014-10-31 2016-05-06 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US20180207236A1 (en) * 2014-10-30 2018-07-26 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
WO2015197446A1 (en) * 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) * 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180207236A1 (en) * 2014-10-30 2018-07-26 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
WO2016069921A1 (en) * 2014-10-31 2016-05-06 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN106687128A (zh) * 2014-10-31 2017-05-17 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法

Also Published As

Publication number Publication date
EP4065597A4 (en) 2024-01-24
CA3161302A1 (en) 2021-06-03
JP2023503472A (ja) 2023-01-30
EP4065597A2 (en) 2022-10-05
AU2020394255B2 (en) 2026-08-06
MX2022006173A (es) 2022-06-14
WO2021107603A2 (en) 2021-06-03
WO2021107603A3 (en) 2021-07-15
ZA202204624B (en) 2023-11-29
KR20210065057A (ko) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
US20230002460A1 (en) 2023-01-05
AU2020394255A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
CN107286248B (zh) 高糖基化人生长激素融合蛋白及其制备方法与用途
CA3096375C (en) Growth differentiation factor 15 agonist compounds and methods of using the same
US20230002460A1 (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CN115916827A (zh) 免疫活化Fc结构域结合分子
KR20240027854A (ko) Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
JP2023514371A (ja) 操作された抗her2二重特異性タンパク質
KR20200011685A (ko) 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
JP2024526080A (ja) インターロイキン15多様体
JP2022502467A (ja) オリゴマー伸長インスリン−fcコンジュゲートおよびそれらの医学的使用
WO2024094755A1 (en) Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
CN116113428A (zh) 白细胞介素-2突变蛋白及其用途
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
US20240082354A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
HK40073215A (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
RU2836280C1 (ru) Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция
CN115702169A (zh) 包含促红细胞生成素多肽的融合蛋白
WO2025252023A1 (en) Modulators for gipr, glp1r and/or gcgr and uses thereof
HK40092774A (en) Methods of using activin receptor type ii variants
CN114401985A (zh) 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
AU2022333099A1 (en) Gdf15 fusion proteins and uses thereof
NZ734482A (en) Fc fusion high affinity ige receptor α-chain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073215

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination